Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. eiwfcsn nistetetotosadevolution Zhang and Xirui options treatment its up-to-date on An focusing 2: review coronavirus syndrome respiratory acute Severe i-in Zhang Xiu-Xiang 3 2 China PR 1 Zhang Xiang COVID-19 of Zhang evolution Xirui and treat- treatment its on on review focusing A review what up-to-date determine evolution An can’t and 2: still investigation. options a we further coronavirus on ment now a syndrome apply needs till respiratory that to but acute issue time bats, an Severe needs be leaving still to host, and determined intermediate trial been the treatment first has of clinical very role virus for the the this only standards plays started of are minimum animal just origin the drugs Chloroquine, of it very achieving kind (Remdesivir, More but the not drugs reported Although from plasma. of few was convalescent way far scale. a vaccine the as still large in expected and are well the only method they as Also, constrained to diagnostic and herb option treatment viral screening, application. Chinese treating and accurate virtual the epidemiology, the and by to fast now, origin, screened a addition to roughly its develop genome in Up provide to to might SARS-CoV-2’s etc.), relating provided. how Favipiravir they of questions on hopefully, be Hydroxychloroquine, clues and, crucial analysis also that, detail the may the in on it of on review Basing treating some us based virus. answering let out the for virus, are contain optimistic. carried SARS-like features better there less other preventing key been the or now, and some already of treating Till less with had that of us becoming with methods studies options. valid comparison is considerable possess its treatment world which and since for the plasma, sequence And convalescent looking of including actively rest trial disease. are clinical the Although the the world in undergo sarbecovirus. the situation drugs subgenus around of to the couple companies belonging but betacoronavirus, pharmaceutical epidemic, of and the lineage Scientists novel controlled a roughly pathogen, be causative has incriminated to The China found China. was Wuhan, SARS-CoV-2, in in termed emerged later outbreak pneumonia-disease unknown an 2019, December In Abstract 2020 28, April 5 4 3 2 1 e aoaoyo onssPeeto n oto fGagogPoic,P China PR Province, Guangdong of Control and Prevention China Zoonosis PR of Guangdong, Laboratory Guangzhou, Key Agriculture, Modern Province, Lingnan for Guangdong Laboratory Guangzhou, Guangdong University, Agricultural China South Medicine, Veterinary of College ot hn giutrlUiest olg fAgriculture of University College Zagazig University Province Agricultural Heilongjiang China Qiqihar, South Engineering, of Institute Sciences Qiqihar Agricultural of Academy Guangdong University Agricultural China South 1,2,3,4 7 1 asrS Mahmmod S. Yasser , ioH Wang Xiao-Hu , ioH Wang Xiao-Hu , 4 asrS.Mahmmod Yasser , 2 iegYang Zipeng , 5 iegYang Zipeng , 8,9 iGoYuan Zi-Guo , 5 n iu Yuan Ziguo and , 1 1 agu Liu Tanghui , 1 agu Liu Tanghui , 1,2,3,4 1 1 1 hoe Ren Zhaowen , hoe Ren Zhaowen , 1 a Yuan Hao , 1 a Yuan Hao , 1,6 Xiu- , 3 , Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. eaooaiu.B sn nisdsqecn ftesml rmteptet oe ooaiu was unknown Viruses coronavirus an of novel Taxonomy by on a Ismail, caused Committee patient, pneumonia 2007; International the have the hosts.(Cavanagh, by from to species name sample found official mammal the was latest and of the patient avian to sequencing a According unbiased of 2019, determined. using range December By wide In 2003) a betacoronavirus. Saif, in & circulating Tang, found be can Coronaviridae Treatments; Betacoronavirus; Introduction COVID-19; host, SARS-CoV-2; intermediate 2; the coronavirus of Evolution syndrome role respiratory the to acute plays determined Severe been animal has of virus kind this investigation. what words: of further determine Key origin a very can’t needs trial the still that first Although we very for issue scale. the now standards an large started minimum leaving till a just the but it on achieving bats, but apply not only reported to be are from was time drugs vaccine far needs More expected Hydroxychloro- still still the plasma. are and Chloroquine, convalescent Also, they (Remdesivir, as application. and well drugs treatment as screening, few clinical herb virtual a Chinese by in the screened they to and only provided. roughly addition fast constrained be hopefully, origin, in a option also its etc.), develop and, Favipiravir may treating to to quine, it detail the how relating treating on now, in questions of clues to review way crucial that, Up the the on us and Basing of let method virus. some diagnostic virus, the answering viral contain SARS-like for accurate trial sequence better features other to genome clinical key treatment SARS-CoV-2’s the the some and of epidemiology, of undergo with analysis us that since drugs the And provide on of with might based disease. couple comparison out the are preventing carried its or been there and treating already world now, of had the methods Till around studies valid companies considerable possess rest pharmaceutical options. which the and treatment plasma, in Scientists convalescent situation for including optimistic. the less looking but and actively epidemic, less the belonging are becoming controlled betacoronavirus, is roughly of world has lineage the novel China of incriminated a Although The be to sarbecovirus. China. found subgenus Wuhan, was in to SARS-CoV-2, in termed emerged later outbreak pathogen, pneumonia-disease causative unknown an 2019, December In Summary Agricul- [email protected] China of [email protected]; PR College [email protected]; Province, Zhang, Guangdong Email: of X-X Guangzhou, Faculty University, A/Prof Medicine, Agricultural Egypt; Animal China Guang- of Sharkia, South Department Guangzhou, Zagazig, ture, University, Diseases, University, Infectious Agricultural Zagazig Mahmmod, China Medicine, Y-S South Veterinary China; Medicine, PR Veterinary Province, of dong College Yuan, Z-G Prof Correspondence: Emirates Arab United 9 Egypt Sharkia, Zagazig, 8 7 6 China PR 510640, 5 China PR Guangdong, Guangzhou, versity, 4 eeiaySine iiin lAnMnsClee ihrClee fTcnlg,A i,AuDhabi, Abu Ain, Al Technology, of Colleges Higher College, Men’s Ain Al University, Division, Zagazig Sciences Medicine, Veterinary Veterinary of Faculty Medicine, China Animal PR of Province, Department Guangdong Guangzhou, Diseases, University, Infectious Agricultural China South China Agriculture, PR of Province, College Heilongjiang Qiqihar, Engineering, of Institute Qiqihar Province Uni- Guangdong Agricultural Guangzhou, Sciences, China ofAgricultural Academy South Guangdong Affairs, Health, Animal Rural of and Institute Agriculture of Ministry of Zoonosis of Laboratory Key aiyi igesrn,pstv-es,evlpdRAvrsfml(ue l,21)that 2016) al., et family(Su virus RNA enveloped positive-sense, single-strand, a is family 2 Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. .Cmiso,22)I swrhntn httecus fsvr n rtclyilptet a ipa a display can patients ill critically and severe of course the that organs.(N. noting multiple worth of failure is of dif- functional shock, onset It and septic the dysfunction 2020) syndrome, coagulation after Commission, distress and week respiratory H. acidosis, one acute diarrhoea.(N. metabolic to hypoxemia and correct progress myalgia and/or to quickly throat, ficult dyspnea can sore have patients nose, severe usually manifestations. runny and patients main congestion, symptoms, Severe the nasal are 2020) as fatigue Commission, such and H. symptoms cough have dry patients fever, few investigation provided. A a epidemiological its be current develop to also the to may on relating how it Based questions on treating features clues crucial of Pathological way that, the & hopefully, the on manifestations and, of and Basing detail Clinical some method virus. genome in answering diagnostic the review SARS-CoV-2’s viral for contain us accurate of features better let and to analysis key virus, fast treatment the some SARS-like and other with on epidemiology, the us origin, based of provide out that more might carried with are they there comparison been as its already optimistic and less had sequence and studies less becoming considerable is 83,369 controlled Since world roughly and the has place. globally, China of taking that cases rest show are the new) figures outbreaks 2020) in These (6,892 concentrated situation WHO(WHO, new). the deaths (4 from deaths but 99,690 Report 3,349 epidemic, with and the Situation China (COVID-19) new) in new) 2019 (89,657 (64 disease confirmed confirmed Coronavirus 1,610,909 the way.(Steenhuysen, that 2020, the Since reported on April 2020) for already 12 al., evaluation also of further et is As for Zhu vaccine chosen its were 2019; they of al., sensitive, development et more PCR and Whist, comparatively 2020) Liu cough on 2020) are dry basing 2016; al., gene fever, developed Dijkman, et RdRp with been the detection.(Corman & 2% already and about Jonsdottir had gene is 2020; E method rate the diagnostic al., fatality viral The et Its 2020) RT-PCR.(Corman to manifestations. al., and estimated main et been Rothe the has 2020; as virus Althaus, fatigue the & of Riou (R0) 2020; number al., closed also reproduction relatively is basic crowdedness the a 1 studies, in be in up-to-date Population transmission the 2020) aerosol to aerosol. Commission, According of of H. can possibility concentrations susceptible.(N. transmission sources infection high generally the contact The is to Asymptomatic is close risk 2020) and exposure There under droplets infection. long-time Zhe, transmission. Respiratory coronavirus a person-to- 2020; 2020) of for a new Commission, Wired., environment routes has with H. main virus 2020; patients infection.(N. the the of mainly al., are world, source of are et a the ability far Rothe over be host’s so also all 2020; the seen from al., determining 2016) infection reports in et Gao, numerous of role & route.(Chan through Yan, key transmission Lu, that, a Wong, confirmed person Wang, plays been Q. also 2015; has protein protein Gao, of It The The & one membrane different 2020) Wang, 2016) cell for is Lu, for typing.(Zhe, Li, responsible responsible protein tropism.(G. virus is is F. (spike) and domain domain for 2004; S2 transmission Each S and used Notably, al., binding domain. always of receptor 2020a) S2 et found for and coding diameter al., was responsible fusion.(He domain is gene et a S1 domain etc.) S1 Zhou its domains, with gene where two al.(P. with functions, into shape M et divided virus and in Zhou be the gene oval could and E of itself or 2020) gene, proteins round al., (S main are et structures the al.(Zhu granules betacoronavirus single-stranded et Typical its positive-sense Zhu 2020) and a by 2020; nm.(Zhe, is envelope, al., it 200 et an coronaviruses, to Lu other with R. 50 to 2020; virus similar al., Therefore, (+ssRNA) et 2019) Hui RNA Woo, S. of analysis.(David & the sarbecovirus Phylogenetic Lau, subgenus the to Li, the on Wong, to according based belongs B) wrong mystery. that lineage betacoronavirus a proven (Beta-CoV a family still been was believed be is had to widely China, identified virus that The is the Province, patients 2020) SARS-CoV-2 of al., of Hubei origin et crowd Wuhan, The Zhu a 2020) in 2019; been announcement.(rfi, Commission, market already official H. wholesale are M. (W. there seafood December, pathogen. origin, late the abbreviation. infecting in in with month, SARS-CoV-2 diagnosed 2, same Coronavirus the Syndrome Respiratory within Acute Severe Then called be should it (ICTV), · 3 - 4 · ihteicbto eidi bu -4dy,msl - as n naeae4 average an and days, 3-7 mostly days, 1-14 about is period incubation the with 9 3 · as(.L et Li days.(Q. 8 Coronaviridae Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. te hnpnois nksadmnswsssetdt eteitreit otfrasotpro of period short a for host intermediate the rejected. was be proposal to all suspected debate, intense was And an minks evolution. after convergent and but by snakes time, explained pangolins, be needed. than may is many Other that viruses in subject confusion endangered the this scholar firmly be their between on to not stated Some investigation identity entitled but further also proved. are sequence pangolins they therefore, group high fully and from research the population not originated Lam’s limited and is possibly comparatively host. places a is intermediate still actually virus the has itself the pangolin be theory that the must indicates the pangolin only whereas the result vague, confirm the still that 2020) Malayan are out al., that points et issues suggesting host.(Lam of evidence intermediate plenty the other However, be some could with China together determined. 85 southern yet displayed coronavirus, 96 in also not pangolin-derived a al.) pangolins is the et with host of (Lam intermediate bats HK that its from be with however, researchers by to 2020b), out al., believed carried et Experiment is Zhou al.(P. virus et the Shi of by reservoir reported natural the Although from? analysing after come death T-cells it in-hospital a from of did implied risk Tim-3 Where al.(Cheng higher further et and a patients. stage, have Cheng PD-1 SARS-CoV-2 by injury symptomatic of study of kidney apparent a with cases expression Finally, patients the 710 discovered the patients. higher had to SARS-CoV-2 addition, 2020) significantly in stage al., In depletion had and precursor et functional SARS-CoV-2 IL-10 and the depletion. with T-cells IL-6, from cell in patients shift decrease serum T that the of with mentioning during marker worth correlated increased a is negatively cells, It PD-1, was T of of cells recovered. and number levels cell T total age) T the of of in of number years reduction count The significant 60 al.(Diao a (over cells. had et patients T care, TNF- Diao elderly (ICU) CD8+ patients, unit especially and care SARS-CoV-2 patients, intensive CD4+, the of SARS-CoV-2 need from that and in samples discovered consciousness, patients 522 2020) of disturbance analysing al., compared symptoms, disease, After et A neurological cerebrovascular SARS-CoV-2. have symptoms. acute often the muscle patients with of severe skeletal patients, that findings found pathological COVID-19 2020) the non-severe al., of et with insight al.(Mao et some Mao provided by of also study had progression study feature rapid tissue, another common SARS-CoV-2 Moreover, heart a a support is the showed Lymphopenia in to heart. COVID-19. changes radiograph the evidence with histological damage chest firm patients obvious directly not in no no the may were is infection al.), There microvascular SARS-CoV-2 there damage. that moderate et liver suggesting but exhibits Xu drug-induced tissue inflammation, or al.(Z. liver active infection Also, et virus lobular lungs. mild Xu two the and by between steatoplasty study differences cytotoxic slight a of with in high concentrations pneumonia a high short, with have be cells to To Th17 found + were was CCR6 cells al.) blood + et T myocardial peripheral amount CCR4 Xu in CD8+ addition, other small granules.(Z. cells increased. In no CD8+ a over-activated. were and but was were effect CD4+ states interstitium, There of pro-inflammatory their number injury. myocardial that The but liver the al.) reduced, suggesting et drug-induced in greatly area, Xu or cells micro- found.(Z. manifold was infection mononuclear moderate damage lobular SARS-CoV-2 of showed parenchymal hepatic infecti- to COVID-19 infiltration coronavirus the due with inflammatory MERS of patients be of and from inflammation may SARS active specimens injury in mild biopsy the those liver and to Besides, steatoplasty similar al.) vascular very et is are disease Xu COVID-19 underlying ons.(Z. 2020) of chronic few Commission, features with with a H. those fatigue pathological only mild.(N. and mild The with relatively elderly and prognosis are the fever children good for low in a prognosis only have Symptoms The show patients poor. condition. patients most critical Mild cases, a current fever. have the obvious patients From no manifestations. even pneumonia and no fever, low or moderate α ocnrtos h eeso L6 L1 n TNF- and IL-10 IL-6, of levels The concentrations. 4 α nptet ihtedsaedcie ihthe with declined disease the with patients in · %t 92 to 5% · %sqec dniy sit’s as identity, sequence 2% · %sqec identity sequence 4% Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. ffc sClrqiede,adClrqie smnindaoe a eotdt eeetv ntreatment in effective be to reported treating was similar above, has mentioned Hydroxychloroquine as ad- since Chloroquine, long-termed of explanation and prevention the plausible does, in by weren’t Chloroquine and helps argued erythematosus which as reasonable be erythematosus, lupus effect seems may lupus systemic effect It systemic with this infection. treat that hospital to the University Hydroxychloroquine Wuhan suspect their from the they in of doctors Hence, patients ministration Medical SARS-CoV-2. Chloroquine. the the of all with that simi- infected that half are only found mechanism is Hospital toxicity and its action People’s disease, wider but Its years a Chloroquine, drug. the 70 to to antimalarial treat than derivative treatment lar the 4-aminoquinoline more to enlarge a for Phosphate to is used safe Hydroxychloroquine, Chloroquine been and used controllable had it it been considered Since had 2020) are reactions. experts spread population.(YSA, patients adverse diseases, widely 100 obvious other be treating than drug-related, in to no more reported been far, EC have was The So there it 2020) stages 6 2020) Moreover, post-entry al., was al., and 2020) et cells entry Wang et al., E6 the lung.(M. in of et both the and autoimmune Wang infection at including functions fusion, SARS-CoV-2’s cells.(M. and body, drug virus/cell the whole The malarial the for 2005) into the that treat displayed al., invasion essential in inhibits et to is al. virus receptors.(Vincent Chloroquine et used that the SARS-viruses’ Wang the by PH of originally (ChiCTR2000029609). of study endosomal is trial glycosylation the the of the It open escalating result with an interferes by 2013). it in cells meanwhile, evaluation al., the the under et of currently Yan infection broad-spectrum is virus’s a 2020; have it Cassone, al., to & and reported Cauda, et the disease been Donatelli, Wang not recently Trani, until Di but M. activity(Savarino, that MERS immune-modulating history 2006; treating as long well in a as further model with capability monkey drug antiviral But cheap on 2020) SARS- a 2020) experiments cured.(Dealmoon, of is few al., Chloroquine, also case a et and first only cured.(Holshue Remdesivir are the been with there America, 2020) already treated as In SARS-CoV-2.(Dealmoon, had needed also now still was China. and are patient in trials Remdesivir, a launched France, with been in treated have Also, been Remdesivir had of patient trials CoV-2 sensitive al., clinical after highly et stage III the 1.76 Wang one phase in was EC functions al.(M. virus cells The Remdesivir stage et 2020) detection, the E6 mature Wang their al., of its of From et by infection to cells). Wang entry.(M. gets study the Huh-7 virus cancer it suppress A the liver before effectively 2016) (human and terminate can line al., researchers to cell Remdesivir with viral et human that Inc. the function.(Warren experimental shown Sciences of antiviral an had chains Gilead initially its 2020) RNA of is fulfills the cooperation cause models, (includes therefore the can viruses animal and under It RNA now and China. of is cells in range Ebola, culture clinicians wide treats a both that against in drug that 1). 2017)) antiviral drug (Table 2020) Spike al., antiviral effective the drugs.(Clercq, an et be as for analogue, SARS/MERS(Sheahan to well adenosine targets as reported an promising cycle also is life considered were the Remdesivir, are drugs in antiviral proteins enzymes broad-spectrum key Those four other similar. as SARS some are virus treat Whist, novel viruses to used the the drugs of of use infection to protein the reasonable inhibit is to of it therefore, MERS number betacoronavirus, and considerable the had to a scientists belongs now, SARS-CoV-2 of to Since effective Up lots trial. disease. be clinical world, the to the whole with started reported the deal even Drugs in and to development society solution under viable the already a to had seeking damage drugs on substantial focus dealt to had started bats.(P. outbreak from the originates Since virus Biorxiv development the website is under on determined or found been available Treatments had be that can thing 2020b) SARS-CoV-2 only al., The et of mystery. Zhou host in still intermediate question the the about debate most ( short, be To https://www.biorxiv.org/ µ .Wit h EC the Whist, M. .Dsuso fwihaia steitreit otedu ihntig leaving nothing, with up end host intermediate the is animal which of Discussion ). 50 · 90 au s0 is value µ ,weesteEC the whereas M, 90 au fRmeii naantteSR-o-’ infection SARS-CoV-2’s the against in Remdesivir of value · 77 5 µ M(SI > 2.7.M age l,22)Currently, 2020) al., et Wang 129.87).(M. 50 au s1 is value 90 au fClrqiei gis the against in Chloroquine of value · 13 µ M(SI > 88 · 0.M Wang 50).(M. Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. h oe iu.Teta sltdsnl el rmsmlso ovlsetptet ftenvlcoron- novel the of patients convalescent of samples of from antibody cells human-originated B of single case isolated first the team index obtained The oxygenation successfully virus. had respiratory novel University Fudan the the the regimen lungs.(Hefei, fever); from their treatment within team with symptom lesions new A CT fever 11 of the with absorption total, better with patients a in displayed treated 11 had In patients 2020) all patients after 4 of participant patients, degrees; rate. vary temperature (14 in participant mortality improved body normal the 14 the reducing to with treatment”, thereby could China, returned trial conventional illness, of storm, + clinical critical Technology As ”Tocilizumab inflammatory the and 2020) and of the of severe patients.(Hefei, Science blocking I to SARS-CoV-2’s of by phase transitioning the University treatment, treating from from conventional patients in team with prevent efficient a together proven by Tocilizumab had out Tocilizumab reported, carried termed trial mAbs clinical a a to According reports. date China(Mak, (mAbs) to in initiated vaccine up antibody recombinant be to developed Monoclonal will according newly and (America) the was vaccine testing trial on I RNA vaccines respectively Phase and DNA 2020) vaccines, (China) basis. America(Dunn, vector this and recombinant on 2020) of out NIH, development that carried the 2020; protein-encoding out been and has antigen, of point vaccines target subunit articles mutation main and the Some to is protein due 2019) virus. S Du, challenges new The from & the many Experts Jiang, against face Huang, progress. vaccine Yang, may certain a Zhou, a SARS-CoV genes.(Y. develop made against to also development cooperated had vaccine had development vaccine China development, and under USA are drugs the As drugs coronavirus. more novel Vaccines the epidemic, papain-like fight out the hydrolase/ to screened (3CL ideas treating was targets new drugs in and of mechanisms 30 effective different about chosen be speaking, ACE2/ have Simply to drugs protease/ selected 2). reported (Table crudely were calculating these with computer above, by mentioned screened SARS-CoV-2 merely as were of drugs, treatment some in symptoms effective As stable proven the with yet which patients not of of drugs effective, of 30% Candidate rate improvement, four 90% the significant over 5th, an experienced key 2020) February shown patients a exacerbation.(Ping;, on had play without of 00:00 cases to confirmed of 60% 214 reported as of treat statistics, also symptoms to to was TCM According herb, used 2020) Chinese provinces interferon- disease.(Hongzhuan, pilot as with the SARS-CoV- known combination treating also on in the in (TCM), Favravavir role 2020) activity medicine inhibits of conducted.(Clercq, traditional its effectively been trial Chinese has reported randomized which Besides, SARS-CoV-2 A study for influenza, 2020) recent (CHICTR09009554) of al., barbiturvir A and treatment et viruses. (CHICTR090029) Wang the M. RNA for 2020; of approved 2.(Clercq, polymerase in analog RNA Hydroxychloroquine guanine of RNA-dependent trials a application rate is Further ongoing. the Favipiravir, disease. are reverse the pneumonia symptoms, of relieve neo-coronary effectively critical course Hydroxychloro- can and the on of which severe the shorten released efficacy pneumonia, discharged/ and of short-term coronary was exacerbation, new a none them of of confirmed of addition, treatment preliminary remaining one the In had and The in use. result illness, quine cases. severe This Hydroxychloroquine 19 clinical developed 2020) of patient’s group in 13.(Publish, the day the February absorption but in after second CT, the enrolled CT chest the and patients in chest the on normal improvement Hydroxychloroquine in of lesions significantly significant Review using progressive improved days. a had by two showed symptoms insufficiency) patients to renal use one had the drug in (previously of patient the significantly improved cases of were days 20 symptoms five treated clinical the had that they found Therefore, SARS-CoV-2. of S rti fSR-o- t. ohv h niioyeeto h iu,poiigalot a providing virus, the on effect inhibitory the have to etc.) SARS-CoV-2 of protein 6 α Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. f1 fiscdn ein a eosrtdta h eoi raiain swl stelnt fthose of length the and bat-SL-CoVZC45 as from well counterparts as the have organization, to both genomic comparison are the in reported, variations that its minor as demonstrated only 14, had with and (98 regions alike N all CoV are coding 7, of proteins, bat-derived M, its highest -E, with the of gene gene SARS-CoV-2 12 the E the of of with comparing identity regions sequence five when 90% deeper, displayed over dive was To similarity ZXC21. and 88% ZC45 mentioned, formed virus is SARS it themselves the As virus and coronavirus MERS SARS-like and Bat-derived coronavirus II) and SARS-like cluster. cluster clade Bat-derived IIb IIa II, (termed bat- clade formed SARS-like clade Within SARS-CoV-2 virus, 2020) one the SARS al., formed and et with I).(Benvenuto Maximum together outcome clade employing CoV same (termed another Novel the analysis SARS-CoV forming shown the tree human-derived had and Phylogenetic the al virus by 2020) et Benvenuto derived formed al., by bat-SL-CoVZC45 is et methods strain: 3 (ML) Lu bat-derived clade likelihood coronaviruses.(R. and and Wuhan bat-derived above; from several mentioned samples and and as 10 GU190215) 1 by number just clade (accession formed formed: bat-SL-CoVZXC21, Bulgaria are is and clades from 2 three Rhinolophussp clade that from 2020a) displayed (KY352407); strains al., has Kenya SARS-related tree et phylogenetic by indicated Zhou that the sequence.(P. composed its of claimed is gene as analysis they Wuhan S further from al, Lu’s and virus from et gene the Results Zhou RdRp virus of by the relative the report analyzing closest of a that study the consist from their is respectively genome RaTG13 from But reported termed genome. the coronavirus also (bat-SL-CoVZC45) of bat-originated 86 CoV had 38% a and SARS-like with groups 2020) bat al., kilobases research HK the et patients 29.8 two the (Chan of from about 89% examining other samples about is study Notably, the had same genome 2020) using genome al., the virus by of al., From et the findings 2020) result et that Lu same al., the GC.(Chan the et reported shown.(R. examined, comparison.(Chan demonstrated was was were sequence had it bat-SL-CoVZXC21 the patients al patients, do Wuhan et and to Chan the bat-SL-CoVZC45 Hongkong by from from from both study samples distinct a with study, is Also, identity branch Lu’s that 2020) long sequence tree In with considerable phylogenetic 2020) 88% composing a a formed further al., clade, an in have was isolated et result thatSARS-CoV-2 bat-SL-CoVZXC21 an showed Lu The and which 2020) formed SARS.(R. bat-SL-CoVZC45 al., al, has with et et it ZXC21.(Zhu together Lu and that from length ZC45 indicated study bats, had the from by originated al. using proven that et strains al. Zhu belong virus et by two SARS-CoV other Zhou Study and by meantime, one SARS-CoV-2 Classification that the that the 94 2020) In reported indicate a of al., with have also that et species had group Wu with same ORF1ab 2020; research identity the in al., lower Lu’s to domains et but MERS, replicase Lu SARS-CoV and conserved 50%).(R. with seven SARS only identity (with with sequence MERS-CoV relationship 79% from its about patients about have remaining more SARS-CoV-2 The out ground. Coronavirus find the Novel To on the walk to to currently relating 2020) patients able findings (YSA, the been have of Evolutionary period. One has don’t recovery illness. one we the critical and and in and vaccines discharged, all severe safe have treating are been is for don’t has plasma means convalescent we effective treated that an when being shown is have especially it been studies and therapeutics, has clinical effective, explore China, and plasma to In convalescent diphtheria. way 2020) program, and antivirals.”(REUTERS, valid rabies emergencies specific very including health diseases a infectious WHO’s other is against of “It solution head life-saving” and Ryan, “effective an Mike proven Dr. to According monoclonal 2020) anti-coronavirus SARS-CoV-2.(Biotechnology, on plasma the working Convalescent neutralize currently SARS-CoV-2. and is of Biotechnology bind antigen An- of Vir that RBD Neutralization called hundreds human (mAbs) the company of screened antibodies recognize development a and the can Also, for obtained them Test. antibodies quickly of candidate tibody and provides many research PCR, that This by found 2020) antibody (BioArt, They the strains. of antibodies region human variable the cloned avirus, · %aioai dniy(.Zo ta. 2020a) al., et Zhou identity.(P. acid amino 6% · %(h ta. 00 uloiesqec dniyt that to identity sequence nucleotide 2020) al., et (Zhu 9% 7 · %.R ue l,22)Mawie prediction Meanwhile, 2020) al., et Lu 7%).(R. Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. ti h a-eie iu hthdtercmiainrte hnteoefo ua patient. Wuhan that from assumed one which the al SARS- than et of rather Lu genome recombination of the team the remarks the had in Concluding by that place couple result virus a took the bat-derived using recombination escalated the By further no 2020a) is which was al., it 2020a), et there al., Zhou that et al.(P. discovered Zhou et CoV-2(P. they Zhou the by sequences, of study (96 SARS-CoV-2’s aligned phylogeny the similarity Nevertheless, of a to sequence 2020) according in high al., RaTG13 SARS-CoV BatCoV 1b. a et from and coronavirus shown of Lu distinct 2020), had gene.(R. tree was al., region (RdRp) the SARS-CoV-2 et bats. RdRp polymerase in al.(Wu that from RNA revealed clustering et Sarbecovirus RNA-dependent Wu subgenus study not complete the by Lu’s but within announced of analysis, recombination is findings phylogenetic of it The conclusion the as same in detected the suggested novel suggests been the as it also in as gene, therefore, had bat-SL-CoVZXC21) 1b S and change gene subgenus (bat-SL-CoVZC45, and position the in strains 1a Topological of happened virus (Zhu members of have bat-derived typical 90%). might tree closest the the (about gene other the in of two 1a virus’s regions 90% with of the encoding than cluster that of main less virus than recombination the be lower that of slightly to analysis indicates 86%) supplementary reported sarbecovirus A (about was 2020) 1b coronavirus al., novel with et the betacoronavirus SARS-CoV. of other of with instead with 1ab) identity place identity (ORF take in might domains 39% mechanism replicase about entry Conserved 66%, only the 2020) around of has al., is change et sequence 1 some mechanism.(Chan protein subunit assumed traditional the the proteins they it the of But outcome, the al., N-terminal Thus, 68%. this et of the entry. al.(Chan on 2015), about of comparing et identity cell Depending al., is Chan after sequence of et domain by acid identified Yang study core mechanism amino was the L. the the a from that that X. result as reported acids 2017; Angiotensin the had Interestingly, it al., amino the 2020), modelling. et use composing homology to through Hu the to affinity SARS 2013; of from able sufficient al., difference the preserves be et some be still still transmission(Ge despite still human-to-human it of and might the analysis that receptor ACE2 enhance structural shows (ACE2) that and may it Since hint experiment 2 2020) (RBD), the modelling enzyme al., gives protein domain converting et the it external binding Lu Through SARS-CoV, an SARS-CoV.(R. entry. receptor the the cell and the to of the domain that close for core mechanism to is Similar a similar possible similarity by verification. to more domain’s composed modelling is closer receptor from still subdomain three-dimensional be the one domain external with following to the the binding comparing a of reported but receptor that by when subdomain is the to proven bat- S1 betacoronaviruses, SARS-CoV-2 closer further the other in is of in is et to domain changed whole-genome happened result Lu binding not deletion the identity.(R. receptor This and remain Despite 93% its SARS-CoV. mutation bat-SL-CoVZXC21, acid 2020) a that and amino al., with suggest bat-SL-CoVZC45 alike C-terminal et 50 the the more Lu about of far strain.(R. acid, position some is derived different amino some for domain greater from the comparatively S2 responsible But for a SARS. the which As has whereas of domain identity, 2020) bat- both S1 sequence strains al., it’s virus with 68% bat-derived that domains only two shown to two with has compares most has bat-SL-CoVZXC21 difference the all. and SARS-CoV-2’s protein is at of SL-CoVZC45 coronavirus Spike analysis surprising SARS-like overview, Detailed not of functions. actually the protein vital is spike in outcome the differentiated mentioned since highly As figure that the other a mentioning genome, with at worth viral variation RaTG13 the is with high in genes it a two variable But has that 2020a) indeed of identity gene al., sequence RdRp et high by and a respectively.(Chan gene study has coronavirus 93 73% S but the SARS of identity), and SARS-CoV-2’s human from and in found 75% and 84% 75% But al about than bat-SL-CoVZC45 about et 2020) at CoVs(less from identity, only Zhou al., nucleotide one 2020) with higher et the al., a all, of have Lu et to that of ZXC21.(R. reported with identity or was identity lowest protein ZC45 78% Spike the SARS-CoV-2’s with al, holds comparing et 13 Chan matter protein no identity and sequence gene S the Contrastingly, 2020) al., et Lu bat-SL-CoVZXC21.(R. · % n h eeo aG3adSR-o- smc ogrta te AS-os(.Zhou SARSr-CoVs.(P. other than longer much is SARS-CoV-2 and RaTG13 of gene S the and 1%, 8 · %woegnm dniy ihtebat-originated the with identity) whole-genome 2% Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. hn o o h upr rmtepbi xeietlisrmn ltomo eeiayCleeo South of College Veterinary of Contributors platform instrument study. experimental public this University. the in Agricultural from analyzed China support or the created for were you data Thank new no as article this Acknowledgments to research applicable not original is no sharing with Data article review a is Statement page, Availability guidelines this author as Data journal’s required the was on approval noted ethical as journal, No data.’ the to. of adhered policies been ethical have the 2020a) that that al., confirm confirmed et authors further The Zhou it bats.(P. gene, of RdRp the 1b ORF1ab.(R. of the Statement alignment in in the Ethical findings happened analysing topological recombination by And with some bat-derived 2020) together indeed in al., 1b analysis is et in phylogenetical there Wu place the 2020; took al., from recombination et that indicated Lu found is was et it it 2020a) possible.(Chan gene, as al., RdRp still strains et and ACE2 ORF1ab Zhou on P. the studying relying 2020; When mechanism al., Angiotensin et entry with Lu cell binding R. of the capable 2020; indicating still al., is (ACE2), domain 2 and binding amino the insertion enzyme receptor and some the of converting analysis meanwhile, verified structural role gene, together investigation. modelling, the the had Three-dimensional further of sequencing plays N-terminal. region a acid its animal S has in needs of of detected virus that C-terminal one also kind the this issue were similar what in replacement an most of detected determine leaving the were origin can’t mutation others, suggests very and still say al Deletion the we et some Although now Zhou pangolin, from say till 2020a) finding some but al., a host, bats, et But intermediate be Zhou 2020) to RaTG13.(P. al., determined et called virus Zhu been strain the 2020; bat-derived al., bat-SL-CoVZXC21.(Chan that and the et bat-SL-CoVZC45 provided Lu is Spike strains; was virus R. its bat-derived 2020; Evidence two moreover, to al., and 2020a) close et is pressure, al., it 2020) positive that et believed al., under widely Zhou et sites It’s mutated.(Benvenuto P. some has distinct 2020; as protein still well al., nucleocapsid but as et and SARS changes Wu The Glycoprotein to structural done. 2020; closer and been comparatively al., has molecular is MERS et has SARS-CoV-2 and Lu the SARS that with it.(R. tree indicated from phylogenetic analyses a these of of construction findings and this sequence for nucleotide factors its influencing of to relevant belongs the SARS-CoV-2 F.-S. determine the al.; As to et needed Huang a still al.; have et are typically patients;(Chen studies diseases healthier Further finding. underlying much 2020) other younger, Zhang, and or infection women & it Wang SARS-CoV-2 older treatment, with than and/or men rate preventive mortality older ideal higher that an noting race. of worth human still development clinical is and the full It for trial for the first standards time Before very minimum tough scale. the the large a started achieving just a be it on not would but apply from roughly reported to far only was time vaccine are still needs drugs expected are More the they plasma. Hydroxychloroquine, Also, Up convalescent for application. and available. Chloroquine, as treatment with is well (Remdesivir, screening, options as deal drugs virtual treatment herb to few by Chinese few affair a the screened still urgent in to but more only addition 2%, al., in constrained and about et etc.), option more Favipiravir only Lu treating a is R. the rate becoming 2020; now, mortality al., is to its et spread betacorona- Though Hui novel its world. S. a Controlling whole analysis(D. be 2019). the various to al., through evident Sarbecovirus et is Wong subgenus Wuhan the 2020; in to outbreak belongs pneumonia that epidemical virus an causes that SARS-CoV-2 Nidovirales oehrwt te w eiu eprtr iess comparison a diseases, respiratory serious two other with together 9 Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. io . ag . a,Y,Ce,X,Lu . ig . hn .(00.RdcinadFntoa Ex- Functional and Reduction (2020). Y. Chen, . . (COVID-19). terror . 2019 L., day, Disease Coronavirus Ning, with same doi:10.1101/2020.02.18.20024364 Y., Patients in Liu, the Cells X., T On Chen, of Y., haustion drug! Tan, C., magic Wang, overnight. B., anti-pneumonia cases Diao, new American 70 (2020). the by C. from surged Drosten, ships news 25 cruise . Good bulletin, . (2020). disease . Dealmoon. communicable K., European D. = RT-PCR. Chu, transmissibles real-time A., doi:10.2807/1560-7917.ES.2020.25.3.2000045 by maladies Meijer, 7917.ES.2020.2825.2803.2000045. (2019-nCoV) R., les Molenkamp, coronavirus City. sur Wuhan novel M., ropeen in Kaiser, 2019 etiology O., of unknown Landt, of Detection pneumonia M., clustering V. of Corman, Report (2019). H. M. W. Commission, Retrieved (2019-nCoV). coronavirus 78e20dbf6e0e320328c6c4048386abde novel from Retrieved 2019 Treatment. Pneumonia args2=242-27110806003998 the Coronavirus New for (2020). H. options N. Commission, Therapeutic asso- (2020). is impairment D. clinical Kidney E. and (2020). from G. L. Epidemiological Xu, . G. L. . . Clercq, Zhang, L., patients. Dong, . COVID-19 Z., of Wang, . death M., study. in-hospital . Zhang, descriptive with K., ciated a Wang, Y., R., China: Han, Luo, Wuhan, Y., in F., Cheng, pneumonia Gong, coronavirus J., novel 2019 Qu, of Lancet X., cases Dong, 99 of M., familial characteristics A Zhou, (2020). N., K.-Y. Yuen, Chen, transmission: . person-to-person . indicating . cluster. coronavirus J., family Yang, novel 6736(20)30154-9 a H., 2019 Chu, of the K.-W., study with K. a associated To, pneumonia K.-H., Kok, of S., cluster Yuan, F.-W., J. Chan, virus. bronchitis from infectious risk avian human- Coronavirus health (2007). coronavirus public D. Cavanagh, Novel address to of platforms case multiple applying first coronavirus. Biotechnology Wuhan the Vir (2020). get V. Biological Biotechnology, Yue Ai 2019- The and antibody. University (2020). originated Fudan M. (2020). Ciccozzi, & BioArt. S., evolution. Angeletti, virus S., for Spoto, doi:10.1002/jmv.25688 evidence A., epidemic: coronavirus Ciccozzi, new M., Giovannetti, D., Benvenuto, interest. References of conflict no declare authors The Science Natural the Interest Program 31972707, of D number 2019A1515011534. Conflicts & grant number R China, grant Technologies of Province, Foundation Key Guangdong Science Emergency of Natural Foundation Pneumonia National Coronavirus the Novel Foshan; by of funded was TL. research and This ZR, tabulation, version. and final collection the information off Fundings writing- signed Z-GY; and writing— HY; approved and and authors X-XZ, ZY All Y-SM, X-HW, XZ, editing, preparation, and draft review writing—original X-XZ; and Z-GY Conceptualization, https://www.nature.com/articles/d41573-020-00016-0 doi:10.1016/S0140-6736(20)30211-7 . act(odn England) (London, Lancet d8735446fe3f262c3af65afccabb7c46 medRxiv 10 04-7602)05-05.doi:10.1016/S0140- S0140-6736(0120)30154-30159. , ora fMdclVirology Medical of Journal 0020.082034.doi:10.1101/2020.02.18.20023242 2020.2002.2018.20023242. , 10001002 e e,38 Res, Vet 9c896c2ed0c4f3d8943f518939a83798 medRxiv uosrelac ultnEu- bulletin : surveillance Euro 2,2127 doi:10.1051/vetres:2006055 281-297. (2), http://117.136.191.144/cache/www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf?ich 2020.2002.2018.20024364. , 10.1002/jmv.25688. , 3,10.2807/1560- (3), The - - Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. i,G . i . ho .C,L,R . i,P . a,W .(09.VrladBceilEtiology Bacterial and Viral (2019). J. W. Tan, & H., China. P. Niu, Qinghai, J., in Patients R. Lu, among Dynamics C., Syndrome Transmission S. Respiratory Early (2020). Zhao, Febrile Z. H., Acute Feng, Li, . of . S., . G. Y., Pneumonia. Liu, Tong, Coronavirus-Infected L., Novel Zhou, of X., China, Wang, P., Wuhan, Wu, in (2020). Proteins. X., Y. Spike Guan, Q., Guan, Coronavirus Li, of . Evolution . and . Function, doi:10.1146/annurev-virology-110615-042301 Y.-S., Structure, 237-261. Liao, (2016). X.-B., F. Ni, Li, for Y.-G., system Tong, universal H.-C., pangolins. Zhu, a Malayan 0 in airway: H.-H., coronaviruses human M. related SARS-CoV-2 Shum, the Identifying T.-Y., and T. Coronaviruses Lam, (2016). R. Dijkman, studies. interaction & chickens. virus-host and R., turkeys in H. coronavirus turkey Jonsdottir, of Pathogenicity coronavirus (2003). M. novel Y. 47 Saif, Dis, 2019 & Avian Y., latest A. Tang, The M., M. continuing - Ismail, The 91 (2020). health Diseases, E. Infectious Petersen, global . for . to Society . coronavirus International coronaviruses China. O., Dar, Wuhan, novel novel R., continuing in Kock, 2019 of The F., outbreak (2020). Ntoumi, latest threat A., E. T. The epidemic Petersen, Madani, . - E., 2019-nCoV . Azhar, infected health I . S., patients O., global D. of Dar, Hui, to R., features Kock, coronaviruses Clinical China. F., novel B. Wuhan, Ntoumi, in Cao, of A., outbreak . T. rich threat Madani, . a epidemic A., . of I. 2019-nCoV Y., Discovery E, Hu, (2017). S., J., D. L. China. Zhao, Hui, Z. Wuhan, L., Shi, in Ren, . coronavirus novel X., . 2019 Li, . with Y., B., coronavirus. Wang, Li, SARS C., of W., Huang, origin Zhang, the Y., into insights X. new Ge, provides 13 coronaviruses L., research Pathog, SARS-related and X. bat Application Yang, of (2020). P., pool C. gene L. H. 2019. Z. Zeng, disease L. Medicine B., Z. coronavirus Chinese X. of Hu, Traditional L. treatment of W. and Y. University f. prevention Shanghai First Y. in (2020). Z. of medicine M. K. Journal Z. Chinese S. W. Pillai, traditional F. . of Y. . R. progress . G. G. H., L. Bruce, C. J., the Hongzhuan, States. Wiesman, at United H., pneumonia the K. in crown Lofy, Coronavirus Novel new S., 2019 of Lindquist, of research Case C., the DeBolt, of L., in M. made domain China! Holshue, been Receptor-binding of has Technology (2004). progress and S. Important Science (2020). of Jiang, o. University subunit & G. developing M., s. for P. Farzan, Hefei, implication W., antibodies: Li, neutralizing Z., and potent Isolation highly Kou, (2013). vaccine. induces S., L. protein Z. Liu, Shi, spike Y., . SARS-CoV . Zhou, . Y., H., receptor. J. He, ACE2 Epstein, the G., uses Zhu, A., that A. coronavirus coro- Chmura, SARS-like doi:10.1038/nature12711 L., new bat X. on a Yang, effects of L., characterization J. therapeutic Li, have Y., may X. drugs Ge, 30 Medica: Materia from of Retrieved Institute navirus. Shanghai volun- (2020). healthy recruiting Y. Fan, start soon will from vaccine Retrieved coronavirus University. potential Emory testing-first-clinical-trial-expands-to-georgia-2020-3 a at of Georgia study in first teers The (2020). A. Dunn, ice ipy e omn 324 Commun, Res Biophys Biochem 1) 1068 doi:10.1371/journal.ppat.1006698 e1006698. (11), 3,5552 doi:10.1637/5917 515-522. (3), https://www.thepaper.cn/newsDetail n netDs 91 Dis, Infect J Int nentoa ora fifciu iess:II ffiilpbiaino the of publication official : IJID : diseases infectious of journal International io ,13 J, Virol 4 doi:10.1186/s12985-016-0479-5 24. , 2,7371 doi:10.1016/j.bbrc.2004.09.106 773-781. (2), h Lancet The 6-6.doi:10.1016/j.ijid.2020.01.009 264-266. , 6-6.doi:10.1016/j.ijid.2020.01.009 264-266. , e nln ora fMedicine of Journal England New 11 https://www.businessinsider.com/coronavirus-vaccine- doi:10.1016/S0140-6736(20)30183-5 . forward nlJMed J Engl N 1-8. , 5633662 Nature doi:10.1056/NEJMoa2001316 . doi:10.1038/s41586-020-2169- . imdEvrnSi 32 Sci, Environ Biomed aue 503 Nature, nuRvVrl 3 Virol, Rev Annu doi:10.1056/NEJMoa2001191 . 77) 535-538. (7477), Academic PLoS (6), (1), Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. u . og . h,W,Lu . a,A .K,Zo,J,...Go .F 21) pdmooy eei Re- Genetic Epidemiology, (2016). F. G. Gao, . . . J., Zhou, K., C. A. Lai, Coronaviruses. J., of Liu, Pathogenesis vaccine. and W., combination, a Shi, on G., work Wong, begin S., R. scientists Su, Baric, hand, in . code . genetic . virus Wuhan B., from With Retrieved J. (2020). Case, Kate. K., E., coronaviruses. J. L. zoonotic Steenhuysen, Gralinski, and D., epidemic antiviral V. both Menachery, the inhibits 9 L., into GS-5734 Med, R. insights antiviral Graham, Broad-spectrum New C., (2017). (2006). A. S. A. Sims, Cassone, P., T. & (2020). Sheahan, R., M. Cauda, Hoelscher, I., . chloroquine. Donatelli, . of L., . effects Trani, C., Di Wallrauch, A., G., no- Germany.Savarino, Froeschl, in 2019 Contact G., Asymptomatic Wuhan an Bretzel, from P., of Infection 2019-nCoV Sothmann, of transmission Transmission M., human-to-human Schunk, C., early 2020. Rothe, of January market. Pattern to game (2020). 2019 market fish December L. 7917.Es.2020.25.4.2000058 with (2019-nCoV), C. do to coronavirus Althaus, nothing vel & has patient J., 0 No. Riou, suggest official epidemic, Wuhan (2020). rfi. approach. valid’ ’very inhibit says can WHO coronavirus, darunavir on-coronavirus-who-says-very-valid-approach-idUSKBN20B1M6 on and therapy plasma Abidol from using Retrieved team: doctors Chinese Lanjuan’s (2020). Li REUTERS. Academician of achievement from Retrieved Major coronavirus. (2020). W. qi, id=6794705852260418052&pbid=6662803681090733575 coro- source=copy new treating in efficacy campaign=client short-term of significant from Treatment has Retrieved Medicine treatment pneumonia. nary erythematosus Chinese Traditional Lupus (2020). on W. Discussion Measures”. Publish, (2020). and H. Causes ”Three Z. of W. Perspective L. Edition) the (Electronic G. from T. Pneumonia W. Manifestati- Coronavirus (APICTH). M. New Neurological Adults S. 18-60 (2020). M. in B. Y. Trial Ping;, Hu, Clinical study. . I series Phase . case A . retrospective (2020). C., a NIH. China: Hong, Wuhan, J., in Chang, COVID-19 Q., doi:10.1101/2020.02.22.20026500 with Retrieved 2020.2002.2022.20026500. He, Patients trials. S., Hospitalized of Chen, clinical ons M., enter Wang, to L., and Mao, vaccine characterisation COVID-19 Genomic homegrown (2020). first W. trials Tan, approves . China . from (2020). . E. binding. H., receptor Wu, Mak, and B., origins Yang, virus P., for implications Niu, coronavirus: England) J., novel 2019 Li, of X., epidemiology Zhao, coronaviruses R., of jump’ Lu, ’host determining features beyond. spike Bat-to-human: and (2015). MERS-CoV, F. G. SARS-CoV, Gao, & Q., Wang, G., Lu, doi:10.3967/bes2019.058 438-445. https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical- 36.doi:10.1126/scitranslmed.aal3653 (396). 04-7602)05-05.doi:10.1016/S0140-6736(20)30251-8 S0140-6736(0120)30251-30258. , link&isappinstalled=0&utm https://www.reuters.com/article/us-china-health-hospital/chinese-doctors-using-plasma-therapy- https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 share&wxshare -0.doi:10.3877/cma.j.issn.2095-8757.2020.01.E001 1-001. , h actIfciu iess 6 Diseases, Infectious Lancet The https://www.thepaper.cn/newsDetail https://www.toutiao.com/i6794705852260418052/?tt count=2&from=groupmessage×tamp=1582033215&app=news rnsMcoil 23 Microbiol, Trends medium=toutiao rnsMcoil 24 Microbiol, Trends 12 2,6-9 doi:10.1016/S1473-3099(06)70361-9 67-69. (2), ios&req 8,4848 doi:10.1016/j.tim.2015.06.003 468-478. (8), forward uoSrel,25 Surveill, Euro id=202002182140140101310741551B04F15F&group 6,4052 doi:10.1016/j.tim.2016.03.003 490-502. (6), 5777936 nlJMed J Engl N 4.doi:10.2807/1560- (4). from=copy hnJGrarc Res Geriatrics J Chin act(London, Lancet doi:10.1056/NEJMc2001468 . link&utm medRxiv c Transl Sci article&utm , - - - Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. hu . ag .L,Wn,X-. u . hn,L,Zag . h,Z-.(00) pneumonia A (2020a). Z.-L. Shi, . . . origin. W., bat Zhang, probable L., of Zhang, coronavirus 2019. new B., in a Hu, with epidemics X.-G., associated Wang, pneumonia outbreak X.-L., coronavirus-infected Yang, new P., for Zhou, and measures Epidemiological Disinfection Disinfection (2020). of (2020). Journal pneumonia. L. R. Chinese crown Fang, Q. new . in W. progress . Zhe, New China. Isolation . (2020). in U. (2015). N., S. outbreak L. Jalali, Y. coronavirus YSA, Z. A., novel Shi, Zhang, 2019 . Y., Wang, the . doi:10.1101/2020.02.10.20021675 M., . of Acute Liu, W., Severe features of Q., Zhang, clinical Progenitor Lu, Q., Direct Y., the Zhang, to Yang, N., Related M. Closely Coronavirus Wang, Coronavirus. chloroquine Bat Syndrome B., Novel drug Respiratory Wang, a Anti-malaria of B., (2013). model. Characterization C. Hu, animal and Jiang, an L., . in X. . infection . Yang, virus H5N1 Y., Wei, A K.-F., influenza doi:10.1038/cr.2012.165 avian Xu, 300-302. treating X., (2), in Li, effective Y., highly Sun, is Z., Zou, Y., COVID-19 of Yan, findings Pathological F.-S. Wang, transmission. . . human syndrome. . distress C., of 2600(20)30076-X Zhang, respiratory risk L., acute Huang, coronavirus for with J., novel Zhang, the associated protein Y., Wang, of spike L., Evolution Shi, (2020). its Z., P. Xu, of Hao, . modeling . and . Sci coronavirus X., outbreak new Life Li, Wuhan A China H., (2020). Zhou, ongoing Y.-Z. J., the Feng, Zhang, J., from . Wang, . P., Chen, . Coronaviruses. X., Z.-G., China. Bat Xu, Song, in of W., disease Epidemiology Wang, respiratory Global Y.-M., human (2019). Chen, with Y. B., associated Yu, C. S., P. Zhao, Woo, F., & Wu, P., K. S. Lau, X., 11 Li, Viruses, P., C. A. Wong, from Retrieved China. Outside People More Infecting coronavirus-is-now-infecting-more-people-outside-china/ Now (2016). Is S. Coronavirus The Bavari, (2020). Wired. . . monkeys. from Retrieved . rhesus 82. – V., in Report Soloveva, Situation source/coronaviruse/situation-reports/20200411-sitrep-82-covid-19.pdf?sfvrsn=74a5d15 virus (COVID-19) L., 2019 Ebola disease R. Coronavirus (2020). against Mackman, WHO. S., GS-5734 A. molecule Ray, doi:10.1038/nature17180 small vaccines K., 381-385. the for M. (7594), chlo- Targets of Lo, protein: and efficacy spike R., Remdesivir MERS-CoV Therapeutic Jordan, (2020). (2016). K., F. G. T. G. Warren, Xiao, Gao, & . J., . Yan, G., therapeutics. vitro. . Lu, and in M., G., Wong, (2019-nCoV) Xu, Q., coronavirus J., Wang, novel Liu, emerged X., recently Yang, the epidemic? doi:10.1038/s41422-020-0282-0 L., inhibit 2019-nCoV Zhang, effectively the R., control roquine to Cao, next M., S. do Nichol, Wang, to . What . (2020). doi:10.1016/S0140-6736(20)30300-7 . 391-393. C. G., (10222), Zhang, spread. T. and & Ksiazek, infection F.-S., E., coronavirus Wang, P. SARS Rollin, of R., inhibitor doi:10.1186/1743-422X-2-69 B. potent 69. Erickson, a (1), S., is Benjannet, Chloroquine (2005). E., T. Bergeron, J., M. Vincent, 2.doi:10.3390/v11020174 (2). doi:10.1007/s11427-020-1637-5 . niia e,133 Res, Antiviral 0) 1-4. (01), io,90 Virol, J 6-7.doi:10.1016/j.antiviral.2016.07.015 165-177. , 6,35-26 doi:10.1128/jvi.02582-15 3253-3256. (6), 13 h actRsiaoyMedicine Respiratory Lancet The Nature doi:10.1038/s41586-020-2008-3 . Nature medRxiv doi:10.1038/s41586-020-2012-7 . 2020.2002.2010.20021675. , doi:10.1016/S2213- . 2 iooyJunl 2 Journal, Virology https://www.who.int/docs/default- elRsac,23 Research, Cell h act 395 Lancet, The https://www.wired.com/story/the- elResearch Cell aue 531 Nature, Sci . Posted on Authorea 22 Apr 2020 — CC BY 4.0 — https://doi.org/10.22541/au.158758017.74950004 — This a preprint and has not been peer reviewed. Data may be preliminary. uoecec iue;HBV Viruses; munodeficiency SARS-CoV-2 SARS-CoV-2 of abbreviations: drugs candidate All some of Summary 2 Table Anti-HIV drugs Candidate HIV Acid; SARS-CoV-2 RNA abbreviations: Broad-spectrum All Remdesivir effective reported Drugs SARS-CoV-2 treating in effective being reported drugs some from of Coronavirus Novel Summary A 1 (2020). Table T. Research, . . . J., 2019. Song, doi:10.1056/NEJMoa2001017 China, pneu- B., Yang, in X., A Pneumonia Li, with (2020b). W., Patients Wang, D., Z.-L. Therapeutics Zhang, and Vaccines Shi, N., MERS-CoV Zhu, in . Advances Domain. (2019). . L. Receptor-Binding Du, the & . origin. on S., Jiang, Based W., bat J., Huang, Zhang, probable Y., Yang, Y., of L., Zhou, coronavirus Zhang, new B., a Hu, with doi:10.1038/s41586-020-2012-7 X.-G., associated Wang, outbreak X.-L., monia Yang, P., Zhou, ++ ua muoecec iue;PH Viruses; Immunodeficiency Human = niatm Montelukast Disulfiram Ebselen Cinnamylamine Cyclosporin PX-12 Carmofur, Bortezomib, Chalcone Shandougen polydatin, Anti-HBV/HCV Name emodin, deoxidant abuse Shikonin, alcohol Treats TDZD-8 Presatovir Tideglusib, Enzaplatovir, Anti-asthma Anti-inflammatory Maribavir Immunosuppressant macrophage Anti-SARS-CoV human targets that Anti-virus diseases neurodegenerative Treats virus syncytial Anti-respiratory Anticancer extract herbal Chinese use Original ra-pcrmRNA Broad-spectrum aeOiia s niia mechanism Antiviral use Original Name rio niIflez nefrstecl ebaesfso ihtevirus. the with fusion membrane’s cell the Interferes viruses RNA of polymerase RNA RNA-dependent the Inhibits PH endosomal the Escalating PH endosomal the Escalating Anti-HIV Anti-Influenza Anti-Influenza disease autoimmune and Malarial Treats erythematosus lupus Systemic Medicine Treats Traditional Chinese Darunavir Arbidol Favipiravir Hydroxychloroquine Chloroquine + / HCV § § eeeauersiaoysnrm ooaiu-;HIV coronavirus-2; syndrome respiratory acute Severe = eeeauersiaoysnrm ooaiu-;RNA coronavirus-2; syndrome respiratory acute Severe = ++ ++ eaii iu HpttsCvrs RNA virus; C /Hepatitis virus B Hepatitis = iue,11 Viruses, h e nln ora fmedicine of journal England New The ¶ iu niia rgRbvrn Galidesivir Ribavirin, drug antiviral virus 14 1.doi:10.3390/v11010060 (1). P oeta hydrogen. potential =

·· PEG-interferon niai,Sqiai,Lpnvr afizmb ioai,Aaaai,Tpaai,Fsmrnvr bcvr liervr atgai,Gitsn Fn 2020) (Fan, Griffithsin, Raltegravir, Elvitegravir, Abacavir, Fosamprenavir, Tipranavir, Atazanavir, Ritonavir, Carfilzomib, Lopinavir, Saquinavir, Indinavir, § ++ aue 579 Nature, 10.1056/NEJMoa2001017. , + α- iu niia rg(ASMR/bl)PetriaeteRAcan ftevrsbfr mature before virus the of chains RNA the Pre-terminate (SARS/MERS/Ebola) drug antiviral virus aand 2a P RbncecAcid; =Ribonucleic 79) 270-273. (7798), + α- + ua Im- Human = 2b =Ribonucleic § rvnsvrsfo sn h iooe ftehs elt yteiepoen eddb h iu Btismcaimo gis ASCV2i tl nnw)a ocnrto f30mcooa,drnvrcnsgicnl nii iu replication virus inhibit significantly can darunavir micromolar, 300 of concentration a at unknown) still is SARS-CoV-2 against on mechanism its (But virus the by needed proteins synthesize to cell host the of ribosomes the using from virus Prevents

·· ¶ ¶ oihbtcl fusion cell inhibit to fusion cell inhibit to Reference Cec,2020) (Clercq, Result bdla ocnrto f1 o3 irmlrcneetvl nii ooaiu pt 0tmscmae ihadu-nrae oto ru q,2020) (qi, 2020) (Ping;, exacerbation without symptoms stable with patients of 30% improvement, significant experienced patients of 60% of group symptoms control the drug-untreated which a of with effective, compared of times rate 60 90% to over up an coronavirus shown inhibit had effectively cases can confirmed micromolar 214 30 to 10 of concentration a cases at 19 Abidol in EC50=61 improvement significant cells: treated, Infecting patients of cases 20 EC50=6 cells: Infecting EC50=0 cells: Infecting · · 90 77 · 88 µ µ µ ,EC90=1 M, EC90=1 M, .Frhreauto fSR-o- a enconducted. been had SARS-CoV-2 of evaluation Further M. · · 13 76 µ µ .Ivligoeteteti mrc n rnersetvl,bt ainshdbe ue.(elon 00 osu ta. 00 .Wn ta. 2020) al., et Wang M. 2020; 2020) al., YSA, et Holshue 2020; 2020; al., et (Dealmoon, Wang (M. reported. was reaction adverse no and shown cured. had been effect had considerable patients treated, both patient respectively, France of and cases America 100 in M. treatment one Involving M. q,2020) (qi, 2020) al., et Wang M. 2020; (Clercq, 2020) (Publish, Reference